```json
{
"content": [
{
"type": "paragraph",
content: "The Temporary Artificial Skin ecosystem extends from biopolymer and collagen suppliers through specialized wound-care manufacturers to hospital theatres and outpatient clinics. Upstream actors synthesize or harvest extracellular-matrix precursors, integrate antimicrobial peptides, and supply sterile substrates. Midstream participants convert these intermediates into sheet, spray, or hydrogel formats, validate sterility, and package single-use constructs. Downstream providers—surgeons, burn centres, and post-acute care facilities—select, apply, and monitor the graft substitute, capturing value via reduced healing time and lower infection risk."
},
{
"type":"list",
"items":[
{ "text": "Biopolymer and collagen suppliers — provide purified biologic matrices and synthetic analogues", "level": 1 },
{ "text": "Antimicrobial peptide technology providers — license and supply infection-resistance functionality", "level": 1 },
{ "text": "Contract sterilization and packaging firms — ensure terminal sterility and barrier integrity", "level": 1 },
{ "text": "Temporary artificial skin manufacturers — convert inputs into finished graft substitutes", "level": 1 },
{ "text": "Medical device distributors — stock, promote, and deliver inventory to clinical sites", "level": 1 },
{ "text": "Regulatory and standards bodies — issue clearance, CE-mark, and biocompatibility guidance", "level": 1 },
{ "text": "Hospital burn and wound-care departments — apply products and assess clinical outcomes", "level": 1 }
]
},
{
"type": "paragraph",
"content": "Adoption control points hinge on regulatory approvals and surgeon training; switching costs are elevated by custom sizing, sterile logistics, and reimbursement coding. Raw-material bottlenecks centre on collagen purity and peptide sourcing, while sterilization capacity can create regional supply gaps. Partnerships between manufacturers and distributors lock in inventory space, limiting new entrants. Value flows upstream when shortages raise substrate prices, and downstream when hospitals bundle grafts into episode-of-care payments."
}
]
}
```
